|
EP2210607B1
(en)
*
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
|
NZ779754A
(en)
|
2009-01-16 |
2023-04-28 |
Exelixis Inc |
Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
AU2011224203A1
(en)
*
|
2010-03-12 |
2012-10-04 |
Exelixis, Inc |
Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin -4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl] -N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
EA030435B1
(ru)
|
2010-07-16 |
2018-08-31 |
Экселиксис, Инк. |
ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
|
|
MX352926B
(es)
|
2010-09-27 |
2017-12-14 |
Exelixis Inc |
Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
|
|
BR112013020362A2
(pt)
|
2011-02-10 |
2018-05-29 |
Exelixis Inc |
processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
MX2013012695A
(es)
|
2011-05-02 |
2014-03-27 |
Exelixis Inc |
Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
|
|
EP2758057B1
(en)
|
2011-09-22 |
2017-05-31 |
Exelixis, Inc. |
Method for treating osteoporosis
|
|
CN104395284A
(zh)
|
2011-10-20 |
2015-03-04 |
埃克塞里艾克西斯公司 |
制备喹啉衍生物的方法
|
|
WO2013166296A1
(en)
|
2012-05-02 |
2013-11-07 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
CA2907334C
(en)
|
2013-03-15 |
2021-12-07 |
Exelixis, Inc. |
Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
|
|
US11564915B2
(en)
|
2013-04-04 |
2023-01-31 |
Exelixis, Inc. |
Cabozantinib dosage form and use in the treatment of cancer
|
|
WO2014165779A1
(en)
*
|
2013-04-04 |
2014-10-09 |
Exelixis, Inc. |
Drug combinations to treat cancer
|
|
BR112016018450A2
(pt)
|
2014-02-14 |
2018-09-18 |
Exelixis Inc |
formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
|
|
EP3119476A1
(en)
|
2014-03-17 |
2017-01-25 |
Exelixis, Inc. |
Dosing of cabozantinib formulations
|
|
EP3174854B1
(en)
|
2014-07-31 |
2022-08-24 |
Exelixis, Inc. |
Method of preparing fluorine-18 labeled cabozantinib and its analogs
|
|
MX382904B
(es)
|
2014-08-05 |
2025-03-13 |
Exelixis Inc |
Combinaciones de fármacos para tratar mieloma múltiple.
|
|
EP3442531A1
(en)
|
2016-04-15 |
2019-02-20 |
Exelixis, Inc. |
Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
|
|
EP3476835A4
(en)
*
|
2016-05-16 |
2020-01-01 |
GB001, Inc. |
CRYSTAL OF A CHINOLINID DERIVATIVE
|
|
TWI831259B
(zh)
|
2018-06-15 |
2024-02-01 |
漢達生技醫藥股份有限公司 |
包含達沙替尼十二烷基硫酸鹽組合物的膠囊
|
|
CA3122576C
(en)
|
2018-12-20 |
2025-11-25 |
Merck Sharp & Dohme Llc |
CRYSTALLINE FORMS OF THE NRTTI COMPOUND OF 4'-ETHYNYL-2-FLUORO-2'-DESOXYADENOSINE
|
|
CN110357814A
(zh)
*
|
2019-07-12 |
2019-10-22 |
上海翔锦生物科技有限公司 |
对甲苯磺酸盐新晶型及其应用
|
|
WO2024163400A1
(en)
|
2023-01-31 |
2024-08-08 |
Handa Oncology, Llc |
Improved cabozantinib compositions and methods of use
|